Trastuzumab deruxtecan - Wikipedia
WEBTrastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the topoisomerase I inhibitor deruxtecan (a derivative of exatecan). [11][12] It is licensed for the treatment of breast cancer or gastric or …
Trastuzumab Deruxtecan in Previously Treated HER2-Low …
WEBJun 5, 2022 · Trastuzumab deruxtecan (formerly DS-8201), an antibody–drug conjugate consisting of a humanized anti-HER2 monoclonal antibody linked to a topoisomerase I inhibitor payload through a...
FDA Approves First Targeted Drug To Treat HER2-Low Breast …
WEBJun 5, 2022 · The drug, trastuzumab deruxtecan (T-DXd), was approved based on a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK) breast medical oncologist Shanu Modi, who presented the findings at this year’s American Society of Clinical Oncology (ASCO) meeting.
Trastuzumab Deruxtecan for Metastatic HER2-Low Breast Cancer
WEBJul 5, 2022 · Trastuzumab deruxtecan, also known as T-DXd, “is the first HER2- targeted therapy shown to provide clinically meaningful improvement in progression-free and overall survival compared with standard chemotherapy in people with HER2-low metastatic breast cancer,” Dr. Modi said at the meeting.
FDA approves fam-trastuzumab deruxtecan-nxki for HER2-low …
WEBOn August 5, 2022, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-low (IHC 1+ or...
Fam-Trastuzumab Deruxtecan-nxki - NCI - National Cancer …
WEBThe monoclonal antibody trastuzumab is chemically linked to a drug called deruxtecan that blocks an enzyme called topoisomerase I. Trastuzumab binds to HER2, a protein involved in cell growth found in large amounts on some cancer cells.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive …
WEBDec 11, 2019 · Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic...
Trastuzumab Deruxtecan (Enhertu) - NCBI Bookshelf
WEBIndication: For the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH–) breast cancer who have received at least 1 prior line of chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.
FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for …
WEBAug 15, 2021 · On December 20, 2019, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki [DS-8201a; T-DXd; tradename ENHERTU (Daiichi Sankyo)] for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regi ….
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated …
WEBJun 5, 2023 · Positive results from an interim analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed that ENHERTU ® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable responses across a broad range of HER2-expressing advanced solid tumors in previously treated patients.
Skip to content